Correlation Between Veracyte and OnKure Therapeutics,

Can any of the company-specific risk be diversified away by investing in both Veracyte and OnKure Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Veracyte and OnKure Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Veracyte and OnKure Therapeutics,, you can compare the effects of market volatilities on Veracyte and OnKure Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Veracyte with a short position of OnKure Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Veracyte and OnKure Therapeutics,.

Diversification Opportunities for Veracyte and OnKure Therapeutics,

-0.68

Correlation Coefficient

Veracyte  OnKure Therapeutics,

Excellent diversification

The 3 months correlation between Veracyte and OnKure is -0.68. Overlapping area represents the amount of risk that can be diversified away by holding Veracyte and OnKure Therapeutics, in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on OnKure Therapeutics, and Veracyte is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Veracyte are associated (or correlated) with OnKure Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of OnKure Therapeutics, has no effect on the direction of Veracyte i.e., Veracyte and OnKure Therapeutics, go up and down completely randomly.

Pair Corralation between Veracyte and OnKure Therapeutics,

Given the investment horizon of 90 days Veracyte is expected to generate 0.68 times more return on investment than OnKure Therapeutics,. However, Veracyte is 1.47 times less risky than OnKure Therapeutics,. It trades about 0.12 of its potential returns per unit of risk. OnKure Therapeutics, is currently generating about -0.27 per unit of risk. If you would invest  3,284  in Veracyte on October 4, 2024 and sell it today you would earn a total of  676.00  from holding Veracyte or generate 20.58% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Veracyte  vs.  OnKure Therapeutics,

Veracyte

Risk-Adjusted Performance

9 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Veracyte are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Veracyte unveiled solid returns over the last few months and may actually be approaching a breakup point.

OnKure Therapeutics,

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days OnKure Therapeutics, has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in February 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Pair Trading with Veracyte and OnKure Therapeutics,

The main advantage of trading using opposite Veracyte and OnKure Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Veracyte position performs unexpectedly, OnKure Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in OnKure Therapeutics, will offset losses from the drop in OnKure Therapeutics,'s long position.

The idea behind Veracyte and OnKure Therapeutics, pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.